Skip to Content

Generic Nourianz Availability

Last updated on July 7, 2021.

Nourianz is a brand name of istradefylline, approved by the FDA in the following formulation(s):

NOURIANZ (istradefylline - tablet;oral)

  • Manufacturer: KYOWA KIRIN
    Approval date: August 27, 2019
    Strength(s): 20MG [RLD], 40MG [RLD]

Has a generic version of Nourianz been approved?

No. There is currently no therapeutically equivalent version of Nourianz available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nourianz. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Microcrystal
    Patent 7,541,363
    Issued: June 2, 2009
    Inventor(s): Kuroda; Kazutoshi & Aoki; Noboru & Ochiai; Toshiro & Uchida; Akihiro & Ishikawa; Yasuhiro & Kigoshi; Makoto & Hayakawa; Eiji & Asanome; Kazuki
    Assignee(s): Kyowa Hakko Kirin Co., Ltd.

    Microcrystals of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione having an average particle size of less than 50 μm; microcrystals of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione having an average particle size of less than 50 μm and a crystallinity of 20% or more or the like, which possess excellent solubility, stability, bioavailability, dispersing property in a pharmaceutical formulation; and the like are provided. A solid pharmaceutical formulation which is characterized by comprising the same is also provided.

    Patent expiration dates:

    • November 13, 2024
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy
    Patent 7,727,993
    Issued: June 1, 2010
    Inventor(s): Kase; Hiroshi & Mori; Akihisa & Waki; Yutaka & Ohsawa; Yutaka & Karasawa; Akira & Kuwana; Yoshihisa
    Assignee(s): Kyowa Hakko Kirin Co., Ltd.

    The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.

    Patent expiration dates:

    • January 28, 2023
      ✓ 
      Patent use: A METHOD OF REDUCING OFF TIME FROM L-DOPA THERAPY, COMPRISING ADMINISTERING, TO A HUMAN PATIENT WITH PARKINSON'S DISEASE, AN EFFECTIVE AMOUNT OF ISTRADEFYLLINE, WHEREIN THE PATIENT CURRENTLY RECEIVES SAID L-DOPA THERAPY
  • Methods of treating patients suffering from movement disorders
    Patent 7,727,994
    Issued: June 1, 2010
    Inventor(s): Kase; Hiroshi & Mori; Akihisa & Waki; Yutaka & Ohsawa; Yutaka & Karasawa; Akira & Kuwana; Yoshihisa
    Assignee(s): Kyowa Hakko Kirin Co., Ltd.

    The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.

    Patent expiration dates:

    • January 18, 2023
      ✓ 
      Patent use: A METHOD OF REDUCING OFF TIME FROM L-DOPA THERAPY, COMPRISING ADMINISTERING, TO A HUMAN PATIENT WITH PARKINSON'S DISEASE, AN EFFECTIVE AMOUNT OF ISTRADEFYLLINE, WHEREIN THE PATIENT CURRENTLY RECEIVES SAID L-DOPA THERAPY
  • Method of stabilizing diarylvinylene compound
    Patent 8,318,201
    Issued: November 27, 2012
    Inventor(s): Uchida; Akihiro & Ishikawa; Yasuhiro & Ueno; Yasuhiko & Kaji; Kiichiro & Aimoto; Masaharu & Kaneko; Naoki
    Assignee(s): Kyowa Hakko Kirin Co., Ltd.

    (wherein Y1 and Y2 may be the same or different and each represents a hydrogen atom, halogen or lower alkyl; and Z and A may be the same or different and each represents substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl) The present invention provides, for example, a method for stabilization of a diarylvinylene compound such as a compound represented by the above formula (I) or the like, or a pharmaceutically acceptable salt thereof in a solid formulation containing the diarylvinylene compound or the pharmaceutically acceptable salt thereof, which comprises allowing an inorganic substance and/or a colorant to exist in the solid formulation, and the like.

    Patent expiration dates:

    • September 5, 2027
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • August 27, 2024 - NEW CHEMICAL ENTITY

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.